Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.
Stage IV Non-small Cell Lung Cancer

About this trial
This is an interventional treatment trial for Stage IV Non-small Cell Lung Cancer focused on measuring NSCLC, Oligometastases, radiotherapy
Eligibility Criteria
Inclusion Criteria:
- Male or female aged 18 to 70 years old;
- Histologically or cytologically confirmed non-small cell lung cancer;
- Stage IV patients with measurable primary tumor and distant metastases number ≤5;
- PS score 0-2;
- Have never received local or systemic anti-cancer treatment, including surgery (biopsy is allowed), first line chemotherapy, targeted therapy or immunotherapy;
- Life expectancy of >3 months;
- Organ function levels must meet the following requirements:
(1)Bone marrow: White blood cell (WBC)≥4.0G/L;neutrophile granulocyte (NEU)≥1.5G/L;platelets (PLT)≥100G/L; hemoglobin (HGB)≥9g/L; (2)Liver and kidney: total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT)≤2.0 × the upper limit of normal (ULN);creatinine≤1.5×ULN; 8.Patient must be willing and able to provide written informed consent.
Exclusion Criteria:
- The amount of metastatic focus >5;
- Patient can't tolerate chemotherapy or targeted therapy;
- Local or systemic anti-cancer treatment had been used for the primary foci and metastatic lymph nodes, including surgery (biopsy is allowed), first line chemotherapy, targeted therapy or immunotherapy;
- Previous or concurrent suffered from other malignancies;
- Concurrent with other serious disease that can not be controlled;
- Women who are breast-feeding or pregnant;
- Have an allergy to pemetrexed, cisplatin, taxanes, targeted medicine and contrast agent;
- Patients with poor obedience or researchers think that the patient may not be able to accomplish the whole trial.
Sites / Locations
- Nanfang Hospital, Southern Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Local Definitive Radiotherapy
No Local Definitive Radiotherapy
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.